Quality of life (QoL) and symptoms in transfusion-dependent patients with myelodysplastic syndromes (MDS) undergoing oral chelation therapy

被引：0
|
作者：
Efficace, Fabio [1 ]
Cottone, Francesco [1 ]
Vignetti, Marco [2 ]
Mandelli, Franco [1 ]
Angelucci, Emanuele [3 ]
机构：
[1] GIMEMA, Italian Grp Adult Hematol Dis, Rome, Italy
[2] GIMEMA Data Ctr, Hlth Outcomes Res Unit, Rome, Italy
[3] Osped Oncol Riferimento Reg A Businco, Rome, Italy
来源：
QUALITY OF LIFE RESEARCH | 2013年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
3092
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Red Bood Cell Transfusion Therapy and Iron Chelation in Patients With Myelodysplastic Syndromes
    Malcovati, Luca
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S305 - S311
  • [42] Disparities in criteria for initiating chelation therapy for iron overload in patients with myelodysplastic syndromes (MDS).
    Bennett, JM
    List, AF
    BLOOD, 2005, 106 (11) : 712A - 712A
  • [43] Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes
    Garcia-Manero, Guillermo
    Diez-Campelo, Maria
    Vellenga, Edo
    Jacoby, Meagan A.
    Merchan, Brayan
    Breems, Dimitri
    Cortelezzi, Agostino
    Doronin, Vadim
    Gomez, Valle
    Beckers, Marielle
    Della Porta, Matteo Giovanni
    Varsos, Helen
    Xiu, Liang
    DeAngelis, Nikki
    Nnane, Ivo
    Rose, Esther
    van Eygen, Koen
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (04) : E111 - E114
  • [44] Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia
    Jamuar, Saumya S.
    Lai, Angeline H. M.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (05) : 299 - 307
  • [45] Combination Oral Chelation in Adult Patients With Transfusion-dependent Thalassemia and High Iron Burden
    Hammond, John
    Thompson, Alexis A.
    Fogel, Mark A.
    Hammond, Katherine
    Kokroko, Jolene
    Kwiatkowski, Janet L.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2019, 41 (01) : E47 - E50
  • [46] Quality of life (QoL) in myelodysplastic syndromes (MDS): an update of results from US & European patient forums
    Heptinstall, K.
    LEUKEMIA RESEARCH, 2007, 31 : S107 - S107
  • [47] THE ORAL IRON CHELATOR DEFERIPRONE DECREASES IRON OVERLOAD AND OXIDATIVE STRESS IN TRANSFUSION DEPENDENT PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    Merkel, D.
    Soffer, S.
    Filanovsky, K.
    Fibach, E.
    Dana, M.
    Mittelman, M.
    Nagler, A.
    Rachmilewitz, E. A.
    LEUKEMIA RESEARCH, 2017, 55 : S53 - S53
  • [48] Review Of Published Survival Evidence For Iron Chelation Therapy (ICT) In Patients With Myelodysplastic Syndromes (MDS)
    Tolley, Keith
    Vieira, Joao
    Foster, Craig
    Strickson, Amanda
    Kundishora, Stephanie
    BLOOD, 2013, 122 (21)
  • [49] Decreased Iron Overload and Oxidative Stress in Transfusion Dependent Patients with Myelodysplastic Syndromes (MDS) with the Oral Iron Chelator Deferiprone
    Merkel, Drorit
    Soffer, Shelly
    Filanovsky, Kalman
    Braester, Andrei
    Fibach, Eitan
    Dana, Mutaz Mohammad
    Ofran, Yishay
    Greenbaum, Uri
    Nagler, Arnon
    Mittelman, Moshe
    BLOOD, 2018, 132
  • [50] Quality of life in transfusion-dependent thalassaemia patients on desferrioxamine treatment
    Dahlui, M.
    Hishamshah, M., I
    Rahman, A. J. A.
    Aljunid, S. M.
    SINGAPORE MEDICAL JOURNAL, 2009, 50 (08) : 794 - 799
12345